Solutions

Htay Htay, David W. Johnson, Giovanni F.M. Strippoli, Jonathan C. Craig, Yeoungjee Cho

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Peritoneal dialysis (PD) is a well-established form of kidney replacement therapy, with possible early survival advantage as compared to hemodialysis. This chapter summarizes the published studies available for neutral pH, low glucose degradation product solution, icodextrin, or amino acid-based solutions in the treatment of peritoneal dialysis and provides recommendations for the nephrologist treating patients on peritoneal dialysis. Most available studies on biocompatible solutions have been too small with too short a follow-up duration to have adequate statistical power to examine hard clinical outcomes, including technique failure and mortality. Peritonitis is one of the most common reasons for patients discontinuing PD therapy. Inflow pain can significantly affect the quality of life of patients on peritoneal dialysis. Icodextrin may slightly increase the risk of rash. Based on the available data, it is uncertain whether once-daily amino acid solution improves nutritional indices in malnourished patients.

Original languageEnglish
Title of host publicationEvidence-Based Nephrology, Second Edition
Subtitle of host publicationVolume 2
EditorsJonathan C. Craig, Donald A. Molony, Giovanni F.M. Strippoli
Place of PublicationHoboken, NJ
PublisherWiley
Chapter47
Pages127-137
Number of pages11
Volume2
EditionSecond
ISBN (Electronic)9781119105954
ISBN (Print)9781119105923
DOIs
Publication statusPublished - 2023

Keywords

  • glucose degradation product
  • hemodialysis
  • inflow pain
  • kidney replacement therapy
  • peritoneal dialysis
  • peritonitis

Fingerprint

Dive into the research topics of 'Solutions'. Together they form a unique fingerprint.

Cite this